Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JI-101 & Everolimus in Advanced Solid Tumors
NCT01149434Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Sep 2010
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of JI-101 in solid tumor, Neuroendocrine Neoplasm (NEN), ovarian cancer and 1 more (2 arms), sponsored by University of Utah. Primary endpoints: Pharmacokinetics Area Under Curve (AUC) (0-inf) of RAD001 at 24 hours, Pharmacokinetics Area Under Curve (AUC) (0-inf) of JI-101 at 24 hours and 2 more. Started Sep 2010; status: terminated.
02
Drugs
JI-101
03
Conditions
solid tumorNeuroendocrine Neoplasm (NEN)ovarian cancercolon cancer
Beyond the preview
Go deeper on NCT01149434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01149434.